Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

Global Glaucoma Therapeutics Market Poised for Growth; Set to Reach US$7.2 Billion by 2030 Glaucoma Therapeutics Market ...

Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery ...

Advanced tools are being deployed by Duke Health and others in the fight against vision loss. STORY HIGHLIGHTS Half of ...

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP reduction, medication reduction, and a favorable safety profile, offering a ...

Bausch + Lomb Corporation (BLCO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc.

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma ...

It is easy to take sight for granted when eyes are working as they should. When vision begins to diminish, people may seek ...

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report), retaining the price target of ...

Potential subjects were excluded if they had had previous glaucoma surgery or laser and also if intraocular surgery or additional SLT procedures were performed after the first treatment.